Drug Profile
Research programme: retrovirally mediated cancer gene therapy - Austrianova
Alternative Names: ReCon retroviral vector - Austrianova; retroviral gene therapy - AustrianovaLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Austrianova
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Austria
- 17 Feb 2006 Preclinical trials in Solid tumours in Austria (unspecified route)